StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.27−0.01 (-3.26%)

Close on Nov 18, 2026Market cap $51.83MP/E –Yield –

Heron Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Heron Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $151.18M, up 1.0% year over year. For fiscal 2025 it was $154.90M, up 7.4% from the year before. The highest annual figure on record is $154.90M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$154.90M+7.4%
FY2024Dec 31, 2024$144.29M+13.6%
FY2023Dec 31, 2023$127.04M+18.0%
FY2022Dec 31, 2022$107.67M+24.7%
FY2021Dec 31, 2021$86.35M-2.6%
FY2020Dec 31, 2020$88.64M-39.3%
FY2019Dec 31, 2019$145.97M+88.4%
FY2018Dec 31, 2018$77.47M+151.8%
FY2017Dec 31, 2017$30.77M+2305.6%
FY2016Dec 31, 2016$1.28M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$37.67M+1.3%
Q1 FY2026Mar 31, 2026$34.71M-10.8%
Q4 FY2025Dec 31, 2025$40.59M-0.5%
Q3 FY2025Sep 30, 2025$38.21M+16.5%
Q2 FY2025Jun 30, 2025$37.20M+3.3%
Q1 FY2025Mar 31, 2025$38.90M+12.2%
Q4 FY2024Dec 31, 2024$40.78M+19.1%
Q3 FY2024Sep 30, 2024$32.81M+4.4%
Q2 FY2024Jun 30, 2024$36.02M+13.4%
Q1 FY2024Mar 31, 2024$34.67M+17.1%
Q4 FY2023Dec 31, 2023$34.23M+14.0%
Q3 FY2023Sep 30, 2023$31.43M+18.4%
Q2 FY2023Jun 30, 2023$31.76M+15.0%
Q1 FY2023Mar 31, 2023$29.62M+26.3%
Q4 FY2022Dec 31, 2022$30.03M+45.4%
Q3 FY2022Sep 30, 2022$26.56M+14.3%
Q2 FY2022Jun 30, 2022$27.63M+23.1%
Q1 FY2022Mar 31, 2022$23.46M+17.2%
Q4 FY2021Dec 31, 2021$20.66M+0.2%
Q3 FY2021Sep 30, 2021$23.23M+16.4%
Q2 FY2021Jun 30, 2021$22.44M-1.0%
Q1 FY2021Mar 31, 2021$20.02M-21.2%
Q4 FY2020Dec 31, 2020$20.61M-41.3%
Q3 FY2020Sep 30, 2020$19.97M-53.2%
Q2 FY2020Jun 30, 2020$22.67M-38.2%
Q1 FY2020Mar 31, 2020$25.40M-19.6%
Q4 FY2019Dec 31, 2019$35.08M+21.6%
Q3 FY2019Sep 30, 2019$42.62M+115.4%
Q2 FY2019Jun 30, 2019$36.66M+112.2%
Q1 FY2019Mar 31, 2019$31.60M+173.2%
Q4 FY2018Dec 31, 2018$28.84M+186.9%
Q3 FY2018Sep 30, 2018$19.79M+130.8%
Q2 FY2018Jun 30, 2018$17.28M+103.0%
Q1 FY2018Mar 31, 2018$11.57M+218.5%
Q4 FY2017Dec 31, 2017$10.05M+686.0%
Q3 FY2017Sep 30, 2017$8.57M–
Q2 FY2017Jun 30, 2017$8.51M–
Q1 FY2017Mar 31, 2017$3.63M–
Q4 FY2016Dec 31, 2016$1.28M–

More Heron Therapeutics figures

See a number that looks wrong?